Related references
Note: Only part of the references are listed.Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma
David M. Gill et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies
Maria Carmen Mir et al.
EUROPEAN UROLOGY (2017)
Renal Mass and Localized Renal Cancer: AUA Guideline
Steven Campbell et al.
JOURNAL OF UROLOGY (2017)
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
JAMA ONCOLOGY (2016)
Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a-T1b Renal Mass and Normal Preoperative Renal Function
Umberto Capitanio et al.
EUROPEAN UROLOGY (2015)
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma
Brian I. Rini et al.
JOURNAL OF UROLOGY (2015)
Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma
Brian R. Lane et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma
Yushi Zhang et al.
PLOS ONE (2015)
Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Jose A. Karam et al.
EUROPEAN UROLOGY (2014)
Renal Function After Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904
Emil Scosyrev et al.
EUROPEAN UROLOGY (2014)
KIDNEY CANCER Progress and controversies in neoadjuvant therapy
Edwin M. Posadas et al.
NATURE REVIEWS UROLOGY (2014)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2013)
Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives
Marc-Olivier Timsit et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery
Brian I. Rini et al.
JOURNAL OF UROLOGY (2012)
Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma
E. Jason Abel et al.
EUROPEAN UROLOGY (2011)
Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis
Maxine Sun et al.
EUROPEAN UROLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Outcome of Stage T2 or Greater Renal Cell Cancer Treated With Partial Nephrectomy
Rodney H. Breau et al.
JOURNAL OF UROLOGY (2010)
Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma
Anil A. Thomas et al.
JOURNAL OF UROLOGY (2009)
Sunitinib for treatment of advanced renal cell cancer: Primary tumor response
Astrid A. M. Van der Veldt et al.
CLINICAL CANCER RESEARCH (2008)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe et al.
LANCET ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Nephron sparing surgery for renal tumors: Indications, techniques and outcomes
RG Uzzo et al.
JOURNAL OF UROLOGY (2001)
Share Paper
